KRAS and non-small cell lung carcinoma: Although the first-line treatment of patients with KRAS mutations in NSCLC is still ICI or platinum-based chemotherapy, based on clinical trial data, KRAS-targeted drug sotorasib or adagrasib has been approved by US Food and Drug Administration for the treatment of patients with KRAS G12C mutations who had received at least one previous systemic therapy (chemotherapy or ICI or both) and had disease progression [21,22,23].